The 3rd MAH Development New Opportunities and Challenges PHARMCHINA Forum successfully concluded.

The third MAH Development New Opportunities and Challenges PHARMCHINA Forum, co-organized by Haibu Pharmaceutical, successfully concluded on December 5, 2019, at the Chongqing International Expo Center.

This forum focused on four major aspects: sorting out the current status and future trend analysis of MAH, investment risk analysis of MAH projects, legal risk point analysis for holders under the MAH system, and key points for building a quality system for MAH. Additionally, it discussed the impact of product registration on the selection of MAH varieties to provide practical 'popular science' on the MAH system for investors. The forum also invited marketing experts to give wonderful speeches on 'Practical Analysis of Volume-based Procurement and Future Selection and Marketing Strategies for Clinical Varieties.'

The forum invited senior experts from various links in the MAH chain to answer questions on-site. It also included a series of recommended premium varieties to introduce differentiated products with potential value to investors, helping MAH become a breakthrough sword for agents. Haibu Pharmaceutical also conducted project roadshows at the forum.

Beijing Haibu Pharmaceutical Technology Co., Ltd. was established in April 2005 and is a high-tech enterprise engaged in the research and development, production, and sales of chemical drugs.

Haibu Pharmaceutical's business covers R&D of high-end active pharmaceutical ingredients (APIs) and pharmaceutical intermediates, related registration and custom production, as well as drug formulation R&D, technology transfer, and technical services. The R&D products involve various therapeutic areas such as mental health (e.g., antidepressants, anxiolytics), sleep disorders, anti-epileptics, analgesics, oncology drugs, cardiovascular drugs, digestive drugs, respiratory drugs among others.

Haibu Pharmaceutical is committed to achieving a series of results based on chemical generics through technological innovations in structural modification of small molecule chemical drugs, process route optimization innovation, challenging crystal forms and process patents. It has applied for 19 related invention patents with 7 granted. The company has commercialized over ten series of high-end APIs and intermediates that have passed multiple site audits by domestic and international clients while receiving recognition and praise.

The company has completed over 100 project transfers to pharmaceutical enterprises so far and obtained more than 60 production and clinical approvals. It has established long-term stable cooperative relationships with clients while accumulating a good reputation in the industry. In the future, Haibu Pharmaceutical will continue to bring more high-quality projects to industry peers and provide more comprehensive services.

Haibu Pharmaceutical sincerely welcomes all enterprises to discuss cooperation!